Yozma

An AI-powered chatbot for hotels revolutionizes the way guests interact with in-room services by enabling seamless cross-selling and upselling. Integrated within smart devices or hotel apps, this AI solution leverages natural language processing (NLP) to communicate with guests in a conversational and personalized manner. From booking spa treatments and restaurant reservations to upgrading rooms or scheduling late checkouts, the chatbot intuitively identifies guest preferences and suggests relevant services. It analyzes data such as guest profiles, previous stays, and real-time behavior to deliver tailored recommendations, boosting both guest satisfaction and revenue. Available 24/7, the chatbot ensures instant responses to guest inquiries, reducing dependence on front-desk staff and enhancing operational efficiency. Additionally, it supports multiple languages, catering to a global clientele and making communication barrier-free. Hotels can integrate the AI chatbot with their property management systems (PMS) and point-of-sale (POS) platforms to streamline service delivery and track guest interactions. The solution empowers hotels to provide a hyper-personalized, tech-forward experience, which appeals to modern travelers. By automating cross-selling and upselling opportunities while improving guest engagement, the chatbot not only enhances the overall stay experience but also drives incremental revenue, making it a vital tool for the hospitality industry.

Meat.The End is focused on advancing plant-based meat alternatives that closely replicate the texture, flavor, and appearance of traditional animal proteins. By employing innovative extrusion processing techniques, the company develops protein texturizing technologies that enhance the sensory experience of plant-based products. Recognizing that texture remains a significant barrier to consumer acceptance of meat alternatives, Meat.The End's solutions aim to improve the mouthfeel and overall eating experience, thereby addressing a critical shortcoming in current plant-based offerings. Through its industrial processes and protein treatment methods, the company enables producers to create nutritionally balanced products that convincingly mimic the characteristics of meat, ultimately providing healthier and more satisfying options for consumers seeking alternatives to animal-based foods.

Meat.The End is focused on advancing plant-based meat alternatives that closely replicate the texture, flavor, and appearance of traditional animal proteins. By employing innovative extrusion processing techniques, the company develops protein texturizing technologies that enhance the sensory experience of plant-based products. Recognizing that texture remains a significant barrier to consumer acceptance of meat alternatives, Meat.The End's solutions aim to improve the mouthfeel and overall eating experience, thereby addressing a critical shortcoming in current plant-based offerings. Through its industrial processes and protein treatment methods, the company enables producers to create nutritionally balanced products that convincingly mimic the characteristics of meat, ultimately providing healthier and more satisfying options for consumers seeking alternatives to animal-based foods.

Fine Data Lab is a digital data analysis company offering digital marketing consulting, analytics, and data analytics solutions.

Illumigyn is focused on enhancing cervical cancer diagnostics through its innovative Gynescope, a compact imaging colposcope that integrates advanced machine vision technologies. This device offers high-resolution imaging with 15-micron detail and features multispectral illumination options, significantly improving the accuracy of cervical exams and minimizing the risk of misdiagnoses. By providing sophisticated imaging capabilities alongside support for complex interventional procedures, the Gynescope aims to deliver optimal clinical outcomes for patients. Through its technology, Illumigyn seeks to address the inherent subjectivity of traditional cervical examinations, ultimately contributing to earlier detection and improved management of cervical cancer.

OP.GG is an e-gaming data analytics company that specializes in creating detailed profiles for gamers by analyzing their gameplay data. This platform enables users to enhance their gaming skills by providing insights into their own performance as well as that of their opponents and friends. OP.GG currently offers services for popular games such as League of Legends, Overwatch, and PUBG, attracting over 28 million monthly users globally. Through its analytics, OP.GG aims to foster a better gaming ecosystem by equipping players with the necessary tools and information to improve their overall gaming experience.

UltraSight is a company focused on enhancing cardiac care through an artificial intelligence-powered ultrasound system. Its technology is designed to assist ultrasound operators in capturing high-quality images more efficiently, thereby facilitating quicker and more accurate diagnoses and treatments for heart disease. By making ultrasound accessible in various healthcare settings, UltraSight aims to improve the quality and timeliness of clinical decisions for patients. The company's innovative approach has gained recognition, winning the TCT 2020 Innovation Competition at the Transcatheter Cardiovascular Therapeutics world conference.

Todos Medical Ltd is an in vitro diagnostics company specializing in the development of innovative testing solutions for various health conditions, including breast cancer, Alzheimer's disease, and COVID-19. The company leverages a multidisciplinary team with expertise in medicine, physics, biochemistry, digital signal processing, and electrical engineering, which provides a competitive edge in the diagnostics field. Todos Medical generates all of its revenue from the United States, focusing on advancing healthcare through its specialized testing services.

Nanox Imaging is a Gibraltar-based company founded in 2011 that specializes in advanced imaging technology for medical, security, and telecommunications applications. The company is pioneering next-generation X-ray emitters utilizing innovative nanotechnology to modernize X-ray imaging, enabling the development of novel 3D imaging systems with superior performance. Central to Nanox's offerings is the Nanox System, which provides a preventative healthcare service known as Medical Screening As A Service (MSaaS). The company has leveraged over two decades of research and development, investing more than $1 billion to create proprietary cold cathode technology that enhances X-ray imaging capabilities. This technology features a chip composed of nano-scale structures, designed through unique nanofabrication techniques, which supports various medical imaging applications and is complemented by additional technologies to maximize its practical benefits in real-world scenarios.

UltraSight is a company focused on enhancing cardiac care through an artificial intelligence-powered ultrasound system. Its technology is designed to assist ultrasound operators in capturing high-quality images more efficiently, thereby facilitating quicker and more accurate diagnoses and treatments for heart disease. By making ultrasound accessible in various healthcare settings, UltraSight aims to improve the quality and timeliness of clinical decisions for patients. The company's innovative approach has gained recognition, winning the TCT 2020 Innovation Competition at the Transcatheter Cardiovascular Therapeutics world conference.

BiSiChem is a biotechnology company dedicated to drug discovery and development, with a particular emphasis on immuno-oncology and central nervous system therapies. The company conducts research to identify molecular drug targets, primarily focusing on anti-cancer agents and treatments for Alzheimer’s dementia. By developing targeted therapies and immunosuppressive drugs, BiSiChem aims to provide innovative, first-in-class treatment options for patients suffering from cancer and neurodegenerative diseases.

NextNine Ltd. is a developer of operational technology security management software, focusing on the protection of industrial and critical infrastructure from cyber security threats. The company's flagship platform facilitates centralized security management for SCADA and ICS environments, addressing vulnerabilities specific to proprietary processes and networks. NextNine's solutions are tailored for sectors such as oil, gas, mining, chemicals, energy, manufacturing, and defense, where the need for remote maintenance and support increases susceptibility to cyber attacks. In addition to its core security software, NextNine offers remote product service, technical support, training, and consulting. With over 6,000 global installations, the company has established itself as a leader in OT security, recognized for its contributions to enhancing cyber security in critical infrastructure. NextNine is headquartered in New York and has been a subsidiary of Honeywell International since 2017.

Kailight Photonics develops optical modules for the telecommunications industry. It offers tunable optical signal regenerator, an optical component that operates with regenerators, optical switches, add/drop multiplexers, and cross-connects. The company's optical transmission, signal regeneration, and wavelength conversion technology provides optical-networking solutions for systems vendors. It provides its products to long-haul network market segments. The company, formerly known as Chilight Technologies, was founded in 2000 and is headquartered in Rehovot, Israel with an additional office in Dallas, Texas. As of May 15, 2007, Kailight Photonics, Inc. operates as a subsidiary of Optium Corporation.

CogniTens, Ltd. specializes in advanced three-dimensional optical measurement solutions for the automotive and manufacturing industries. The company offers a range of products, including Optigo, a portable platform for dimensional measurement, and OptiCell, an automated system for off-line recurring measurements on the production floor. Additionally, CogniTens provides software solutions such as CoreView Plan for developing measurement programs, CoreView Pro for analyzing and reporting measurement data, and CoreView Lite for viewing results. Their offerings facilitate industrial engineering activities, including tooling, part production, assembly, quality assurance, and process control. Founded in 1995 and headquartered in Ramat Hasharon, Israel, CogniTens serves automotive original equipment manufacturers, tier-one suppliers, tool and die companies, and other engineering organizations through a network of distributors.

Predix Pharmaceuticals is a drug discovery and development company specializing in small-molecule drugs that target G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine that utilizes a proprietary algorithm for computer modeling the 3D structures of GPCR targets. Its advanced technologies enable high-throughput in silico screening of millions of compounds against these models, facilitating lead optimization through an integrated medicinal and computational platform. Predix's drug candidates are aimed at treating various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In August, the company expanded its capabilities in drug discovery through a merger with Physiome Sciences Inc., enhancing its expertise in ion channel research.

NextNine Ltd. is a developer of operational technology security management software, focusing on the protection of industrial and critical infrastructure from cyber security threats. The company's flagship platform facilitates centralized security management for SCADA and ICS environments, addressing vulnerabilities specific to proprietary processes and networks. NextNine's solutions are tailored for sectors such as oil, gas, mining, chemicals, energy, manufacturing, and defense, where the need for remote maintenance and support increases susceptibility to cyber attacks. In addition to its core security software, NextNine offers remote product service, technical support, training, and consulting. With over 6,000 global installations, the company has established itself as a leader in OT security, recognized for its contributions to enhancing cyber security in critical infrastructure. NextNine is headquartered in New York and has been a subsidiary of Honeywell International since 2017.

CogniTens, Ltd. specializes in advanced three-dimensional optical measurement solutions for the automotive and manufacturing industries. The company offers a range of products, including Optigo, a portable platform for dimensional measurement, and OptiCell, an automated system for off-line recurring measurements on the production floor. Additionally, CogniTens provides software solutions such as CoreView Plan for developing measurement programs, CoreView Pro for analyzing and reporting measurement data, and CoreView Lite for viewing results. Their offerings facilitate industrial engineering activities, including tooling, part production, assembly, quality assurance, and process control. Founded in 1995 and headquartered in Ramat Hasharon, Israel, CogniTens serves automotive original equipment manufacturers, tier-one suppliers, tool and die companies, and other engineering organizations through a network of distributors.

Can-Fite BioPharma is an Israeli biopharmaceutical company engaged in the discovery and clinical development of therapeutics for cancer and inflammatory diseases. The company specializes in developing orally bioavailable small molecule drugs that target the A3 adenosine receptor (A3AR). Can-Fite's lead drug candidate, Piclidenoson, is currently in a Phase III trial aimed at treating psoriasis. Additionally, Namodenoson, another key product, is advancing into a Phase III trial for hepatocellular carcinoma, the most prevalent form of liver cancer, and is also undergoing a Phase IIb trial for non-alcoholic steatohepatitis. With a robust pipeline of proprietary compounds in advanced clinical stages, Can-Fite is focused on addressing significant unmet medical needs in autoimmune-inflammatory conditions and cancer.

Predix Pharmaceuticals is a drug discovery and development company specializing in small-molecule drugs that target G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine that utilizes a proprietary algorithm for computer modeling the 3D structures of GPCR targets. Its advanced technologies enable high-throughput in silico screening of millions of compounds against these models, facilitating lead optimization through an integrated medicinal and computational platform. Predix's drug candidates are aimed at treating various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In August, the company expanded its capabilities in drug discovery through a merger with Physiome Sciences Inc., enhancing its expertise in ion channel research.

HyWire Ltd., established in 1999 and headquartered in Netanya, Israel, specializes in the development, manufacturing, and marketing of silicon-based search and classification VLSI components and subsystems. The company focuses on providing high-end solutions for switching and routing equipment, addressing the growing demand for speed and capacity in Internet connectivity. As bandwidth requirements continue to rise due to an increasing number of users and various network applications such as video streaming, voice over IP, e-commerce, and enterprise services, HyWire's products are designed to meet these critical needs in the telecommunications landscape.

NextNine Ltd. is a developer of operational technology security management software, focusing on the protection of industrial and critical infrastructure from cyber security threats. The company's flagship platform facilitates centralized security management for SCADA and ICS environments, addressing vulnerabilities specific to proprietary processes and networks. NextNine's solutions are tailored for sectors such as oil, gas, mining, chemicals, energy, manufacturing, and defense, where the need for remote maintenance and support increases susceptibility to cyber attacks. In addition to its core security software, NextNine offers remote product service, technical support, training, and consulting. With over 6,000 global installations, the company has established itself as a leader in OT security, recognized for its contributions to enhancing cyber security in critical infrastructure. NextNine is headquartered in New York and has been a subsidiary of Honeywell International since 2017.

Predix Pharmaceuticals is a drug discovery and development company specializing in small-molecule drugs that target G-protein coupled receptors (GPCRs) and ion channels. The company employs an innovative 3D Discovery and Optimization Engine that utilizes a proprietary algorithm for computer modeling the 3D structures of GPCR targets. Its advanced technologies enable high-throughput in silico screening of millions of compounds against these models, facilitating lead optimization through an integrated medicinal and computational platform. Predix's drug candidates are aimed at treating various conditions, including anxiety, Alzheimer's disease, and pulmonary arterial hypertension. In August, the company expanded its capabilities in drug discovery through a merger with Physiome Sciences Inc., enhancing its expertise in ion channel research.

Globecom Interactive Commerce, Inc. is a US-Israel company that specializes in broadband-enabled solutions for the presentation of products and services. Established in 1998 and headquartered in Chantilly, Virginia, the company has research and development facilities in Herzliya, Israel. Globecom is recognized for its innovative software solutions that facilitate the creation, management, and delivery of rich dynamic media across various platforms, enabling businesses to enhance the productivity of both new and existing Internet market channels.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Cardonet is a provider of IT support and technology services, dedicated to maximizing revenue and supporting business growth. Established in 1999, the company offers a comprehensive range of managed IT services, focusing on both the design and management of technology solutions. Cardonet assists businesses in enhancing their operational efficiency and gaining a competitive advantage through effective technology utilization. In addition to routine IT support, such as resolving technical issues and managing server emergencies, the company also collaborates with e-marketplaces to create and maintain transactive catalogs that improve the buyer's experience and boost marketplace transactions. With a commitment to hands-on service, the directors of Cardonet remain actively involved in client engagements, ensuring that their ethos of "making IT happen" is at the core of their operations.

HarmonyCom is a privately held, venture-backed telecommunications software solutions provider founded in 1997. It has its U.S. headquarters in Ann Arbor, Michigan with operations in London and Tel Aviv. The lead investor in HarmonyCom is Iscal Holdings, Ltd., a private Israeli investment company that focuses on emerging high-tech companies. Additional funding has been received from Yozma Venture Capital. HarmonyCom's premier product is Harmony, a software solution that automates and orchestrates the delivery of broadband data services, allowing for measurable improvements in customer satisfaction, faster time-to-market for new products, reduced operational costs, and improved accuracy of information.

Telegate is a developer of the most reliable and feature-rich VoIP system.

NextNine Ltd. is a developer of operational technology security management software, focusing on the protection of industrial and critical infrastructure from cyber security threats. The company's flagship platform facilitates centralized security management for SCADA and ICS environments, addressing vulnerabilities specific to proprietary processes and networks. NextNine's solutions are tailored for sectors such as oil, gas, mining, chemicals, energy, manufacturing, and defense, where the need for remote maintenance and support increases susceptibility to cyber attacks. In addition to its core security software, NextNine offers remote product service, technical support, training, and consulting. With over 6,000 global installations, the company has established itself as a leader in OT security, recognized for its contributions to enhancing cyber security in critical infrastructure. NextNine is headquartered in New York and has been a subsidiary of Honeywell International since 2017.